Product Details
PMS-Sacubitril-Valsartan
Sacubitril + Valsartan48.6 mg + 51.4 mg
Tablet
DIN/PIN/NPN
02564440
Manufacturer
Pharmascience Inc.
Formulary Listing Date
2026-03-31
Unit Price
1.8530
Amount MOH Pays
1.8530
Coverage Status
Limited Use Product Chronic-Use Medication
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
C09DX04
Interchangeable Products
| DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
|---|---|---|---|
| 02446936 | Entresto | 3.7060 | 1.8530 |
| 02564440 | PMS-Sacubitril-Valsartan | 1.8530 | 1.8530 |
| 02549026 | Sandoz Sacubitril-Valsartan | 1.8530 | 1.8530 |
LU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| 497 | Indefinite | For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF to reduce the incidence of cardiovascular (CV) death and HF hospitalization, if all of the following clinical criteria are met: - Reduced left ventricular ejection fraction (LVEF) (Less than 40%); - Patient has NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB); and - In combination with a beta blocker and other recommended therapies, including an aldosterone antagonist (if tolerable). |
Requirements